Smallpox
📧 Sign up to get email alerts when something new happens for Smallpox.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS [Phase 2]
A Phase 2 clinical trial update evaluating safety and immunogenicity of oral tecovovirmat (TPOXX) given for 28 days in combination with the …
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa [Phase 2]
Ongoing Phase 2 randomized trial evaluating the safety, reactogenicity, and immunogenicity of an mRNA-based Mpox vaccine candidate in Africa…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection
The document provides an update on the VA-005 trial evaluating vaccinia immune globulin intravenous (VIGIV) for treating complications of sm…
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: MVA Post-Event: Administration Timing and Boost Study [Phase 1, Phase 2]
A Phase 1/2 clinical trial update evaluating the timing of post-exposure MVA vaccination and booster dosing for smallpox, with results poste…
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age [Phase 1, Phase 2]
The study reports the completion of a Phase 1/2 trial evaluating the safety, tolerability, and immune response of multiple doses of the inve…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: High Dose IMVAMUNE® in Vaccinia-Naive Individuals [Phase 2]
Phase 2 trial evaluating a high-dose IMVAMUNE smallpox vaccine in vaccinia-naive adults; results were posted in 2025.
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure
Clinical trial update for the antiviral Tecovirimat (ST-246) used to treat exposure to orthopoxviruses, including smallpox and monkeypox; th…
-
CLINICAL_TRIALS trial_result · 2025-01-15Clinical Trial Update: Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults [Phase 1]
A Phase 1 study assessing the bioequivalence of Brincidofovir Form H and Form II tablets in healthy adults has completed.
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days [Phase 3]
Phase 3 trial assessing the safety, tolerability, and pharmacokinetics of orally administered tecovirimat (TPOXX) over 28 days for smallpox;…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders [Phase 4]
Phase 4 study evaluating drug-drug interactions between TPOXX (tecovirimat) and phosphate binders has completed and results were posted.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG [Phase 4]
Phase 4 study evaluating safety, tolerability, and pharmacokinetics of tecovirimat (TPOXX) in adults weighing more than 120 kg with smallpox…
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years [Phase 2, Phase 3]
Phase 2/3 trial evaluating immunogenicity, reactogenicity, and safety of the VACΔ6 vaccine in adults 18-60; study completed.
-
CLINICAL_TRIALS trial_result · 2021-05-27Clinical Trial Update: Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial [Phase 3]
A Phase 3 trial evaluating the lot consistency of Freeze-Dried MVA-BN for smallpox has been completed, with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally [Phase 2]
Phase 2 trial comparing lyophilized versus liquid IMVAMUNE and a lower-dose intradermal liquid form for smallpox; results posted after compl…
-
CLINICAL_TRIALS trial_result · 2020-10-12Clinical Trial Update: A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects [Phase 2]
Phase II trial comparing liquid-frozen and freeze-dried IMVAMUNE (MVA-BN) smallpox vaccine formulations in vaccinia-naïve healthy subjects; …
-
CLINICAL_TRIALS trial_result · 2020-04-02Clinical Trial Update: Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection [Phase 2]
Phase II randomized trial assessing safety and immunogenicity of MVA-BN Smallpox Vaccine in HIV-infected immunocompromised subjects; study c…
-
CLINICAL_TRIALS trial_result · 2019-12-05Clinical Trial Update: A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® [Phase 3]
A Phase 3 non-inferiority trial comparing MVA-BN Smallpox vaccine to ACAM2000 in vaccinia-naïve adults 18-42; study completed with results p…
-
CLINICAL_TRIALS trial_result · 2019-02-18Clinical Trial Update: An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees [Phase 2]
Phase II open-label study assessing immunogenicity and safety of a single IMVAMUNE booster given two years after prior vaccination in former…
-
CLINICAL_TRIALS trial_result · 2019-01-10Clinical Trial Update: A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects [Phase 2]
A Phase 2 study assessing safety and immunogenicity of one and two doses of IMVAMUNE smallpox vaccine in vaccinia-experienced adults aged 56…
-
CLINICAL_TRIALS trial_result · 2019-01-10Clinical Trial Update: Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine. [Phase 2]
A Phase 2 dose-finding study evaluated immunogenicity at three dose levels of IMVAMUNE (MVA-BN) smallpox vaccine; study completed.
-
CLINICAL_TRIALS trial_result · 2019-01-09Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects [Phase 2]
Phase 2 randomized, double-blind trial evaluating immunogenicity and safety of MVA-BN (IMVAMUNE) smallpox vaccine in healthy subjects; resul…
-
CLINICAL_TRIALS trial_result · 2019-01-03Clinical Trial Update: A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects [Phase 3]
A Phase 3 trial evaluated the immunogenicity and safety of three consecutive production lots of IMVAMUNE (MVA-BN) smallpox vaccine in health…
-
CLINICAL_TRIALS trial_result · 2018-07-05Clinical Trial Update: Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study [Phase 1]
Phase 1 safety study of Poly-ICLC aimed at preventing respiratory viral infections has completed, evaluating its safety in conditions includ…
-
CLINICAL_TRIALS trial_result · 2017-11-28Clinical Trial Update: A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat [Phase 3]
Phase 3 clinical trial update evaluating safety, tolerability, and pharmacokinetics of tecovirimat (TPOXX) for smallpox; the study completed…
-
CLINICAL_TRIALS trial_result · 2015-12-11Clinical Trial Update: Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® [Phase 2]
Phase II trial of IMVAMUNE to assess safety and immunogenicity for smallpox has completed. Results were posted on December 11, 2015.